In utero exposure to perfluorooctanoate (PFOA) or perfluorooctane sulfonate (PFOS) did not increase body weight or intestinal tumorigenesis in multiple intestinal neoplasia (Min/+) mice.
We examined whether perfluorooctanoate (PFOA) or perfluorooctane sulfonate (PFOS) had obesogenic effects and if they increased spontaneous intestinal tumorigenesis in the mouse model C57BL/6J-Min/+ (multiple intestinal neoplasia) after in utero exposure. The dams were exposed to PFOA or PFOS (0.01, 0.1 or 3.0mg/kg bw/day) by po gavage on GD1-17. The Min/+ and wild-type offspring were terminated at week 11 for examination of intestinal tumorigenesis or at week 20 for obesogenic effect, respectively. Body weights of the dams and pups were recorded throughout life. Food intake was determined at week 6 and 10. Blood glucose (non-fasted) was measured at week 6 and 11. No obesogenic effect of PFOA or PFOS was observed up to 20 weeks of age. PFOA or PFOS did not increase the incidence or number of tumors in the small intestine or colon of the Min/+ mice or affect their location along the intestines. Feed intake was not affected. There were some indications of toxicity of PFOA, but not of PFOS. There was lower survival of pups after 3.0mg/kg PFOA, lower body weight in pups after 3.0 and possibly 0.1mg/kg PFOA, and increased relative liver weight after 0.01 and possibly 0.1mg/kg PFOA. Plasma glucose was lower after 0.01 and 0.1mg/kg PFOA. In conclusion, exposure to PFOA and PFOS in utero with the doses used did not have obesogenic effect on either Min/+ or wild-type mice, at least not up to 11 or 20 weeks of age, nor increased intestinal tumorigenesis in Min/+ mice.
Department of Food, Water and Cosmetics, Division of Environmental Medicine, Norwegian Institute of Public Health, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway. Electronic address: ha.thi.ngo@fhi.no.
Ha Thi
HT
Ngo
Department of Food, Water and Cosmetics, Division of Environmental Medicine, Norwegian Institute of Public Health, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway. Electronic address: ragna.hetland@fhi.no.
Ragna Bogen
RB
Hetland
Department of Exposure and Risk Assessment, Division of Environmental Medicine, Norwegian Institute of Public Health, NO-0403 Oslo, Norway. Electronic address: azemira.sabaredzovic@fhi.no.
Azemira
A
Sabaredzovic
Department of Exposure and Risk Assessment, Division of Environmental Medicine, Norwegian Institute of Public Health, NO-0403 Oslo, Norway. Electronic address: line.smastuen.haug@fhi.no.
Line Småstuen
LS
Haug
Department of Food, Water and Cosmetics, Division of Environmental Medicine, Norwegian Institute of Public Health, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway. Electronic address: inger-lise.steffensen@fhi.no.
Inger-Lise
IL
Steffensen
D017738:Alkanesulfonic Acids / Q000097:blood / Q000633:toxicity*; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002210:Caprylates / Q000097:blood / Q000633:toxicity*; D063646:Carcinogenesis / Q000187:drug effects*; D004435:Eating / Q000187:drug effects; D005260:Female; D005466:Fluorocarbons / Q000097:blood / Q000633:toxicity*; D007414:Intestinal Neoplasms / Q000139:chemically induced*; D008099:Liver / Q000187:drug effects; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000139:chemically induced*; D009929:Organ Size / Q000187:drug effects; D011247:Pregnancy; D012098:Reproduction / Q000187:drug effects; D013154:Spleen / Q000187:drug effects
D017738:Alkanesulfonic Acids; D001786:Blood Glucose; D002210:Caprylates; D005466:Fluorocarbons; C023036:perfluorooctanoic acid; C076994:perfluorooctane sulfonic acid
In utero exposure; Intestinal tumorigenesis; Min/+ mouse; Obesogen; Perfluorooctane sulfonate; Perfluorooctanoate